Targeting EGFR and ALK in NSCLC: current evidence and future perspective

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeted therapies, particularly tyrosine kinase inhibitors (TKIs), have transformed non-small cell lung cancer (NSCLC) treatment.
• Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene fusions are key targets in advanced NSCLC.

Purpose of the Study:

• To review current treatment strategies for NSCLC with EGFR mutations or ALK rearrangements.
• To discuss emerging therapies and future clinical options for managing resistance.

Main Methods:

• Literature review of clinical trials and research on targeted therapies for NSCLC.
• Analysis of mechanisms of resistance to EGFR and ALK inhibitors.
• Discussion of novel therapeutic approaches and future directions.

Main Results:

• First-line TKIs offer significant progression-free and overall survival benefits over chemotherapy in advanced NSCLC with EGFR mutations or ALK rearrangements.
• Acquired resistance to TKIs is a major challenge, leading to eventual treatment failure.
• Emerging therapies show promise in overcoming resistance and improving long-term outcomes.

Conclusions:

• Targeted therapy for EGFR-mutated and ALK-rearranged NSCLC has improved patient prognosis.
• Addressing treatment resistance is crucial for further enhancing survival and quality of life.
• Future strategies will likely involve novel inhibitors and combination therapies.